首页 | 本学科首页   官方微博 | 高级检索  
检索        


Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older
Authors:Lisa A Jackson  Alejandra Gurtman  Martin van Cleeff  Robert W Frenck  John Treanor  Kathrin U Jansen  Daniel A Scott  Emilio A Emini  William C Gruber  Beate Schmoele-Thoma
Institution:1. The Group Health Research Institute, Group Health, Seattle, Washington, United States;2. Pfizer Inc, Pearl River, New York, United States;3. Triangle Medical Research Associates, Cary, North Carolina, United States;4. Department of Pediatrics, Cincinnati Children''s Hospital Medical Center, Cincinnati, Ohio, United States;5. University of Rochester Medical Center, Rochester, New York, United States;6. Pfizer GmbH, Berlin, Germany
Abstract:

Background

Unlike free polysaccharide vaccines, pneumococcal polysaccharide conjugate vaccines (PCVs) induce a T cell-dependent immune response and have the potential to provide an extended duration of protection with repeated vaccinations.

Methods

This was an extension of a previous study in pneumococcal vaccine-naïve adults aged 50–64 years in which adults 60–64 years of age were given 13-valent PCV (PCV13) or 23-valent pneumococcal polysaccharide vaccine (PPSV23) and adults aged 50–59 were given PCV13. In this follow up study conducted about 4 years later, the 60–64 year olds initially given PCV13 received PCV13 or PPSV23, and those initially given PPSV23 received another PPSV23. All adults aged 50–59 years were re-vaccinated with PCV13. Anti-pneumococcal opsonophagocytic activity (OPA) titers were measured before and 1 month after vaccination.

Results

A second PCV13 given about 4 years after a first vaccination induced OPA titers that were significantly higher than those following the initial vaccination for 7 of 13 serotypes in the older group, and 6 of 13 serotypes in the younger group, and responses to the remaining serotypes were largely non-inferior. In contrast, OPA titers following revaccination with PPSV23 were statistically significantly lower for 9 of the 13 serotypes, and non-inferior for the remaining serotypes, when compared to the responses to the first PPSV23. OPA titers in the older adults who received PPSV23 after initial PCV13 were significantly higher than those following a first PPSV23 for 10 of the 13 serotypes.

Conclusion

In adults 50 to 64 years of age, initial vaccination with PCV13 establishes an immune state that results in recall anti-pneumococcal responses upon subsequent vaccination with either conjugated or free polysaccharide vaccine. In contrast, initial vaccination with PPSV23 results in an immune state in which subsequent PPSV23 administration yields generally lower responses compared with the initial responses.
Keywords:ACIP  United States Advisory Committee on Immunization Practices  AE  adverse event  CI  confidence interval  CRM197  cross-reactive material 197  GMR  geometric mean ratio  GMT  geometric mean titer  OPA  opsonophagocytic activity  PCV  pneumococcal polysaccharide conjugate vaccine  PCV13  13-valent pneumococcal conjugate vaccine  PPSV23  23-valent polysaccharide vaccine  RCDC  reverse cumulative distribution curve  SAE  serious adverse event
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号